CoChat

Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease

Open access
Xiong, Yongjie, Qu, Yi, Min, Zhe, Wu, Jun, Zhang, Suming, Xue, Zheng · 2022 · International Journal of Nanomedicine

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 7 of the 17 sources its claims cite were checked for support.

Abstract

An ultrasmall superparamagnetic iron oxide nanoparticle coupled with Aβ(16–20) and Tat-PTD was developed as a targeted MRI contrast agent to detect Aβ deposits in transgenic mice.

Overview

CoChat Summary

TL;DR

A targeted MRI contrast agent, Tat-PTD-USPIO-Aβ(16-20), was developed by coupling ultrasmall superparamagnetic iron oxide nanoparticles with Tat-PTD and the Aβ(16-20) peptide. It crossed endothelial cell membranes in vitro, bound senile plaques, and decreased T2 MRI signal in APP/PS1 transgenic mice, with no significant toxicity versus control for the coupled agent.

Key findings

  • The coupling efficiency was 97.75% for Tat-PTD-USPIO-Aβ(16-20) and 94.62% for Tat-PTD-USPIO-Aβ(1-40); nanoparticles had a core diameter of 6–10 nm, hydration radius ~50 nm, surface charge −8.003 mV, and R2 relaxivity of 140 mmol⁻¹ sec⁻¹.
  • In vitro, CMECs incubated with FITC-Tat-PTD-USPIO-Aβ(16-20) showed green fluorescence and potassium ferrocyanide iron staining, indicating membrane penetration; MRI showed decreased T2 signal in cells incubated with the contrast agent.
  • Toxicity testing: 20 μM Aβ(1-40) or Aβ(16-20) alone was toxic (n=3; p<0.001), but there was no significant difference for Tat-PTD-USPIO-Aβ(16-20) vs control or Tat-PTD-USPIO vs control; coupling decreased toxicity relative to Aβ(16-20) or Aβ(1-40) alone.
  • In vivo, red fluorescence from the contrast agent matched green Thioflavin-S–stained senile plaques, and dark spots on T2-weighted MRI matched these fluorescence distributions in APP/PS1 transgenic mice; no similar spots appeared in wild-type mouse sections.

Methods

  • Amino-USPIO nanoparticles were coupled with Tat-PTD and Aβ(16-20) or Aβ(1-40) using EDC/NHS chemistry, ultrafiltration, and BCA protein assays to measure coupling efficiency.
  • In vitro studies used primary cultured cerebral microvascular endothelial cells (CMECs) with FITC-Tat-PTD-USPIO-Aβ(16-20) at 0.45 μmol Fe/mL for 48 h, fluorescence microscopy, potassium ferrocyanide staining, 3.0T MRI, and MTT toxicity assays over 72 h with seven groups, including 20 μM Aβ(1-40) or Aβ(16-20).
  • In vivo, five APP/PS1 transgenic mice and five age-matched wild-type C57Bl/6J mice (6–8 months old) received tail-vein injections of 0.1 mmol Fe/kg Tat-PTD-USPIO-Aβ(16-20) at 10 μL/s, repeated 24 h later; 7.0T MRI was performed 2 h after the second injection, followed by frozen brain sections (10–20 μm) stained with Thioflavin-S. Statistical analysis used SPSS v13.0 with one-way ANOVA and Student-Newman-Keuls tests, significance at P<0.05, and at least three independent experiments.

Limitations

  • Stated: the safety of Tat-PTD was not verified in human subjects because it was obtained from the HIV-1 construct; quantitative experiments are needed to explore statistical differences; and whole-body distribution of the MRI contrast agent should be assessed in future studies.
  • Evident from the text: in vivo groups were small (five APP/PS1 transgenic and five wild-type mice), and the MRI/histology findings are largely qualitative, with no quantitative MRI signal analysis reported.
  • Evident from the text: no human data are presented; findings are limited to cell culture and a mouse model.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ijn.s351830

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 2 Not valid · 9 Not checked · 33 Own results and interpretations

21 more claims

Create a free account to see all 49 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 7
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Research works printed but not linked: 2

  1. Li, 2011, Zhonghua Yi Xue Za Zhi, 91, 876
  2. Zhan, 2011, Zhong Hua Shen Jing Ke Za Zhi, 44, 500

Cited by

See all 4

Metadata

Authors
Xiong, Y., Qu, Y., Min, Z., Wu, J., Zhang, S., & Xue, Z.
Affiliations
  • Tongji Hospital (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
Venue
International Journal of Nanomedicine
Published
2022-02
Volume
Volume 17
Pages
927-936
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
OpenAlex
W4214734340
Cited by
4
References
20
Citations by year
2026: 2 · 2023: 2
FWCI
0.31
Type
journal article
Language
en
Open access
Locations
International Journal of Nanomedicine (publishedVersion, cc-by-nc)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
Keywords
amyloid-beta imaging, Alzheimer's disease, targeted MRI contrast agents, ultrasmall superparamagnetic iron oxide, blood-brain barrier penetration, transgenic mouse model, contrast agent toxicity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.